Insight Molecular Diagnostics Inc.
LSE: 0KCC.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Joshua Riggs
- Employees
- 46
- Headquarters
- Nashville, United States
- IPO year
- 2018
- Market cap
- $151.0M
- Website
- https://imdxinc.com
Loading 0KCC…
Loading profile data…Frequently asked questions about 0KCC
What does Insight Molecular Diagnostics Inc. (0KCC.L) do?
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one...
Where does 0KCC.L trade?
Insight Molecular Diagnostics Inc. (0KCC.L) trades on the London Stock Exchange.
What sector is 0KCC.L in?
Insight Molecular Diagnostics Inc. (0KCC.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Insight Molecular Diagnostics Inc.?
Joshua Riggs is the chief executive officer of Insight Molecular Diagnostics Inc. (0KCC.L).
Where is Insight Molecular Diagnostics Inc. headquartered?
Insight Molecular Diagnostics Inc. is headquartered in United States.
Does 0KCC.L pay a dividend?
Insight Molecular Diagnostics Inc. (0KCC.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0KCC.L go public?
Insight Molecular Diagnostics Inc. (0KCC.L) completed its initial public offering in 2018.